The short version of lipogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Lariocidin (abbreviated as LAR) is a naturally occurring lasso peptide antibiotic. It is the first lasso peptide reported to inhibit protein synthesis in bacteria through interactions with the ribosome. LAR kills a broad spectrum of bacteria, including multiple human pathogens that are classified as priority pathogens by the World Health Organization such as Acinetobacter baumannii, Klebsiella pneumoniae, Staphylococcus aureus, and Escherichia coli.
=== Sexual deviance === CPA is used as an antiandrogen and form of chemical castration in the treatment of paraphilias and hypersexuality in men. It is used to treat sex offenders. The medication is approved in more than 20 countries for this indication and is predominantly employed in Canada, Europe, and the Middle East. CPA works by decreasing sex drive and sexual arousal and producing sexual dysfunction. CPA can also be used to reduce sex drive in individuals with inappropriate sexual behaviors, such as people with intellectual disability and dementia. The medication is also used to reduce sexual behavior diagnosed as self-harmful, such as masochism. CPA has comparable effectiveness to medroxyprogesterone acetate in suppressing sexual urges and function but appears to be less effective than GnRH modulators like leuprorelin and has more side effects. High-dose CPA significantly decreases sexual fantasies and sexual activity in 80 to 90% of men with paraphilias. In addition, it has been found to decrease the rate of reoffending in sex offenders from 85% to 6%, with most of the reoffenses being committed by individuals who did not follow their CPA treatment prescription. It has been reported that in 80% of cases, 100 mg/day CPA is adequate to achieve the desired reduction of sexuality, whereas in the remaining 20% of cases, 200 mg/day is sufficient. When only a partial reduction in sexuality is desired, 50 mg/day CPA can be useful.
Although progesterone does not have significant AR-mediated androgenic or antiandrogenic activity, it is a precursor and intermediate, albeit distant, in the biosynthesis of androgens from cholesterol. For this reason, there has been some speculation that exogenous progesterone could be transformed into androgens by certain tissues that express the requisite enzymes. Progesterone is converted by 17α-hydroxylase into 17α-hydroxyprogesterone; 17α-hydroxyprogesterone is converted by 17,20-lyase into androstenedione; and androstenedione is converted by 17β-hydroxysteroid dehydrogenases into testosterone. CYP17A1, the cytochrome P450 gene that encodes 17α-hydroxylase and 17,20-lyase, is expressed mainly in the gonads (ovaries and testes) and the adrenal glands. However, while it is theoretically possible that progesterone could be transformed in the body into androgens, no androgenic effects have been observed in animal studies. In addition, clinical studies, in which women were treated with 100 to 300 mg/day oral progesterone, have found no or only a small increase in levels of 17α-hydroxyprogesterone, and no change in androgen levels, including of dehydroepiandrosterone, androstenedione, and testosterone. In these studies, levels of estradiol and cortisol, which progesterone is also a precursor of, did not change either, although levels of 11-deoxycorticosterone increased significantly.
Conversely, low orexin signaling may result in low hedonic tone and orexin receptor antagonists are of interest for the potential treatment of addiction. In line with these findings, suvorexant and other orexin receptor antagonists have not shown misuse liability in animal studies in rats and non-human primates. Paradoxically however, orexin receptor antagonists, including suvorexant, lemborexant, and daridorexant, have consistently shown drug-liking responses in human studies of recreational sedative users. Suvorexant at higher-than-approved doses (40, 80, and 150 mg vs. 20 mg maximum recommended dose) showed similar drug liking to the Z-drug zolpidem (15 and 30 mg) in such individuals. On the other hand, it showed lower misuse potential on all other measures (including an overall rate of misuse potential adverse event of 58% for zolpidem and 31% for suvorexant). In another study, suvorexant at a dose of 150 mg showed greater drug liking than daridorexant (50 mg) but similar drug liking to zolpidem (30 mg) and higher doses of daridorexant (100–150 mg) in recreational sedative users. There was no apparent dose–response relationship for positive measures of misuse potential with suvorexant, in contrast to zolpidem. In the phase III clinical trials, misuse potential adverse events were reported in 3.0% with placebo, 4.1% with 15 or 20 mg suvorexant, and 2.6% with 30 or 40 mg suvorexant. The misuse liability of suvorexant is considered to be at most modest, and further research is needed to characterize the misuse potential of orexin receptor antagonists.
Sources: en.wikipedia.org
Some sources say that the El Niños of 2006-07 and 2014-16 were also Central Pacific El Niños. Recent years when La Niña Modoki events occurred include 1973–1974, 1975–1976, 1983–1984, 1988–1989, 1998–1999, 2000–2001, 2008–2009, 2010–2011, and 2016–2017. The recent discovery of ENSO Modoki has some scientists believing it to be linked to global warming. However, comprehensive satellite data go back only to 1979. More research must be done to find the correlation and study past El Niño episodes. More generally, there is no scientific consensus on how/if climate change might affect ENSO. There is also a scientific debate on the very existence of this "new" ENSO. A number of studies dispute the reality of this statistical distinction or its increasing occurrence, or both, either arguing the reliable record is too short to detect such a distinction, finding no distinction or trend using other statistical approaches, or that other types should be distinguished, such as standard and extreme ENSO. Likewise, following the asymmetric nature of the warm and cold phases of ENSO, some studies could not identify similar variations for La Niña, both in observations and in the climate models, but some sources could identify variations on La Niña with cooler waters on central Pacific and average or warmer water temperatures on both eastern and western Pacific, also showing eastern Pacific Ocean currents going to the opposite direction compared to the currents in traditional La Niñas.
=== The 53Mn – 53Cr chronometer === The short-lived 53Mn-53Cr chronometer is based on the radioactive decay of 53Mn to 53Cr with a half-life of 3.80 ± 0.23 million years. Because manganese and chromium are moderately volatile elements, their fractionation in the cooling solar nebula makes this chronometer particularly suited for dating volatile element depletion events in early Solar System materials. The initial homogeneous distribution of 53Mn in the Solar System, a prerequisite for its use as a chronometer, was established in early studies of Solar System materials. Applied to meteorites, 53Mn-53Cr systematics have provided key insights into the origin of chondrite parent bodies and the volatile element depletion history of the early Earth. The volatile element depletion of proto-Earth was established no later than ~3 million years after the formation of calcium-aluminium-rich inclusions (CAIs), contemporaneous with the dissipation of the protoplanetary disk, while full planetary accretion was completed within ~70 million years.
=== Arrest in Arizona === On February 7, 2026, Peters was arrested in Scottsdale, Arizona, on suspicion of dangerous drug possession, with court documents describing him as carrying Adderall and Anavar, and possession of a forged instrument at a bar, after attempting to gain entry using a fake ID. According to officers, he was shown on stream asking patrons at the bar for Adderall. He was released from custody the following day and soon tweeted that the charges were "straight up political persecution". Prosecutors dropped the charges on February 11, 2026, because of the low likelihood of conviction.
=== Synthesis === One method for preparing β-phenethylamine, set forth in J. C. Robinson and H. R. Snyder's Organic Syntheses (published 1955), involves the reduction of benzyl cyanide with hydrogen in liquid ammonia, in the presence of a Raney-Nickel catalyst, at a temperature of 130 °C and a pressure of 13.8 MPa. Alternative syntheses are outlined in the footnotes to this preparation. A much more convenient method for the synthesis of β-phenethylamine is the reduction of ω-nitrostyrene by lithium aluminium hydride in ether, whose successful execution was first reported by R. F. Nystrom and W. G. Brown in 1948. Phenethylamine can also be produced via the cathodic reduction of benzyl cyanide in a divided cell.
Melvin Calvin and Andrew Benson, along with James Bassham, elucidated the path of carbon assimilation (the photosynthetic carbon reduction cycle) in plants. The carbon reduction cycle is known as the Calvin cycle, but many scientists refer to it as the Calvin-Benson, Benson-Calvin, or even Calvin-Benson-Bassham (or CBB) Cycle. Nobel Prize–winning scientist Rudolph A. Marcus was later able to discover the function and significance of the electron transport chain. Otto Heinrich Warburg and Dean Burk discovered the I-quantum photosynthesis reaction that splits CO2, activated by the respiration. In 1950, first experimental evidence for the existence of photophosphorylation in vivo was presented by Otto Kandler using intact Chlorella cells and interpreting his findings as light-dependent ATP formation. In 1954, Daniel I. Arnon et al. discovered photophosphorylation in vitro in isolated chloroplasts with the help of P32. Louis N. M. Duysens and Jan Amesz discovered that chlorophyll "a" will absorb one light, oxidize cytochrome f, while chlorophyll "a" (and other pigments) will absorb another light but will reduce this same oxidized cytochrome, stating the two light reactions are in series.
Sources: en.wikipedia.org
=== Normal values === Reference ranges for blood tests of plasma renin activity can be given both in mass and in international units (μIU/mL or equivalently mIU/L, improperly shown as μU/mL or U/L, confusing mcU/mL used where Greek μ not available), with the former being roughly convertible to the latter by multiplying with 11.2. The following table gives the lower limit (2.5th percentile) and upper limit (97.5th percentile) for plasma renin activity by mass and MCU, with different values owing to various factors of variability of reference ranges:
== Mechanism == AGRP has been demonstrated to be a competitive antagonist of melanocortin receptors, specifically MC3-R and MC4-R. The melanocortin receptors, MC3-R and MC4-R, are directly linked to metabolism and body weight control. These receptors are activated by the peptide hormone α-MSH (melanocyte-stimulating hormone) and antagonized by the agouti-related protein. Whereas α-MSH acts broadly on most members of the MCR family (with the exception of MC2-R), AGRP is highly specific for only MC3-R and MC4-R. This inverse agonism not only antagonizes the action of melanocortin agonists such as α-MSH but also further decreases the cAMP produced by the affected cells. The exact mechanism by which AgRP inhibits melanocortin-receptor signalling is not completely clear. It has been suggested that Agouti-related protein binds MSH receptors and acts as a competitive antagonist of ligand binding. Studies of Agouti protein in B16 melanoma cells supported this logic. The expression of AgRP in the adrenal gland is regulated by glucocorticoids. The protein blocks α-MSH-induced secretion of corticosterone.
doi:10.1371/journal.pone.0010958. PMC 2881040. PMID 20532040. Sibuet, M.; Olu, K. (1998). "Biogeography, biodiversity and fluid dependence of deep-sea cold-seep communities at active and passive margins". Deep-Sea Research Part II: Topical Studies in Oceanography. 45 (1–3): 517–567. Bibcode:1998DSRII..45..517S. doi:10.1016/S0967-0645(97)00074-X. Vinn, O.; Hryniewicz, K; Little, C.T.S.; Nakrem, H.A. (2014). "A Boreal serpulid fauna from Volgian-Ryazanian (latest Jurassic-earliest Cretaceous) shelf sediments and hydrocarbon seeps from Svalbard". Geodiversitas. 36 (4): 527–540. doi:10.5252/g2014n4a2. S2CID 129587761. Retrieved 9 January 2014. Vinn, O.; Kupriyanova, E.K.; Kiel, S. (2013). "Serpulids (Annelida, Polychaeta) at Cretaceous to modern hydrocarbon seeps: Ecological and evolutionary patterns". Palaeogeography, Palaeoclimatology, Palaeoecology. 390: 35–41. Bibcode:2013PPP...390...35V. doi:10.1016/j.palaeo.2012.08.003. Retrieved 9 January 2014.
The first comprehensive analysis of the city's tens of thousands of abandoned and dilapidated buildings took place in the spring of 2014. It found that around 50,000 of the city's 261,000 structures were abandoned, with over 9,000 structures bearing fire damage. It further recommended the demolition of 5,000 of these structures. Between 2000 and 2010, Detroit lost a quarter of its population. More people left Detroit during this time—237,500—than fled New Orleans after Hurricane Katrina—140,000. However, from 2010 to 2018, Detroit saw the biggest growth in racial diversity of any city analyzed by a US news study. This is not the racial diversity most other cities experienced. Opposite of the white flight most cities experienced, where whites fled cities for safer suburbs, Detroit saw an influx of white residents into the downtown and midtown areas. The Midtown and downtown areas have increasing population density, while African American neighborhoods remain without good access to public services. The city's poverty rate remains several times higher than the national average.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.